Equities

Zota Health Care Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Zota Health Care Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,204.50
  • Today's Change10.50 / 0.88%
  • Shares traded8.79k
  • 1 Year change+45.14%
  • Beta0.7441
Data delayed at least 15 minutes, as of Mar 05 2026 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zota Health Care Limited is an India-based pharmaceutical company, which is engaged in the manufacturing and marketing of pharmaceutical products catering to domestic and international markets. It engages in manufacturing, marketing, and exporting a range of pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products. The Company’s business model comprises three vertical, namely Domestic, Exports, and Retail Pharmacy Chain. Its Domestic Marketing business vertical involves the direct distribution of generic drugs, OTC products, and other pharmaceutical products. Its product portfolio offers over 4,000 therapeutic product categories such as generics, OTC products, allopathic, ayurvedic, and others. Its Retail Pharmacy Chain business operates a chain of approximately 880 pharmacy stores under the brand Davaindia. It exports to over 30 countries. Its Domestic products include AZIVAR-100 DT Tab, AZIVAR-250 Tab, AZIVAR-500 Tab verticals, AZIVAR-CX Tab, among others.

  • Revenue in INR (TTM)4.73bn
  • Net income in INR-726.58m
  • Incorporated2000
  • Employees519.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bliss GVS Pharma Ltd8.68bn1.09bn22.81bn966.0021.18--15.492.6310.1810.1880.97--------8,986,598.00--6.04--7.5452.6546.3313.189.45--8.44--8.275.133.2711.72-2.825.180.00
Hikal Ltd17.46bn-130.00m22.97bn2.06k----15.681.32-1.05-1.05141.83--------8,465,567.00--4.78--7.0055.4748.00-0.74475.71--1.21--14.834.214.2930.461.46-2.773.13
Dishman Carbogen Amcis Ltd27.97bn1.19bn25.71bn1.11k21.65--5.740.91947.577.57178.50--------25,287,880.00---0.7247---0.900584.9674.274.25-2.77--1.31----3.665.82102.11-54.07-11.91--
Gufic BioSciences Ltd8.97bn500.38m27.43bn1.99k54.83--33.843.064.994.9989.42--------4,513,114.00--10.27--16.1155.8746.415.5810.48--2.73--1.311.6316.69-19.1425.1513.6414.87
Orchid Pharma Ltd8.11bn188.68m28.67bn737.00152.02--54.283.533.723.72160.07--------11,006,770.00--1.40--1.7236.8235.892.142.75--0.4822----12.4813.768.13--104.06--
RPG Life Sciences Ltd6.74bn2.03bn29.83bn1.33k14.72--13.344.43122.51122.51407.37--------5,061,758.00--21.05--27.7864.3463.2830.0716.68--174.47--24.9212.2611.71109.0344.5827.3937.97
Gujarat Themis Biosyn Ltd1.59bn477.88m31.31bn221.0065.51--54.0819.654.394.3914.62--------7,209,322.00--30.70--34.3762.7868.0329.9935.51--55.73-----11.2012.12-17.5615.55104.6124.95
Aarti Drugs Ltd25.22bn2.03bn32.90bn1.28k16.33--12.361.3022.0722.07274.99--------19,639,960.00--9.09--14.3936.3522.098.038.08--7.00--6.07-5.605.74-1.903.5329.8514.87
Senores Pharmaceuticals Ltd5.89bn1.02bn34.41bn194.0033.35--26.475.8522.4122.41130.31--------30,336,080.00--------58.73--17.48----5.94----85.64--86.17------
SMS Pharmaceuticals Ltd8.97bn895.91m35.07bn1.47k36.97--27.933.9110.1310.13101.51--------6,102,851.00--5.58--7.6632.5533.789.718.05--5.85--5.7210.3613.7038.7516.9723.629.86
Innova Captab Ltd14.97bn1.32bn37.03bn1.95k27.97--21.042.4723.1323.13261.52--------7,676,703.00--10.02--15.0036.2627.208.858.72--12.45----15.0227.2135.9535.69109.94--
Sun Pharma Advanced Research Co Ltd531.36m-2.68bn40.07bn316.00------75.41-8.26-8.261.64--------1,681,519.00---60.53---129.98-4.34-3.83-504.20-168.34---8.82-----5.00-1.3511.55---28.16--
Zota Health Care Ltd4.73bn-726.58m41.87bn519.00------8.86-23.98-23.98157.24--------9,108,992.00---7.79---10.5757.2242.02-15.34-8.01---3.71----62.3225.23-293.08--49.400.00
Supriya Lifescience Ltd7.35bn1.85bn49.92bn515.0026.92--23.636.7923.0523.0591.47--------14,280,700.00--18.45--21.6372.3359.6225.1925.45--129.43--3.5922.1117.4557.8020.6945.94--
F D C Ltd20.78bn2.17bn60.48bn6.86k27.91--21.822.9113.3113.31127.73--------3,030,531.00--11.35--12.9667.9260.8510.4314.75--47.92--6.348.509.42-12.592.1525.37--
Data as of Mar 05 2026. Currency figures normalised to Zota Health Care Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

0.44%Per cent of shares held by top holders
HolderShares% Held
WhiteOak Capital Asset Management Ltd.as of 31 Jan 2026131.05k0.43%
Polar Capital LLPas of 31 Dec 20251.18k0.00%
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.